Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776688 | 0.90 | EGFR (0.67) | EGFRERBB2MAP2K1SRCMAP3K8 | |
| SCHEMBL4766938 | 0.88 | MAP2K1 (0.64) | EGFRERBB2MAP2K1MAP3K8 | |
| SCHEMBL4775921 | 0.88 | SRC (0.64) | EGFRERBB2MAP2K1SRCMAP3K8 | |
| SCHEMBL4775833 | 0.87 | MAP2K1 (0.60) | EGFRERBB2MAP2K1MAP3K8 | |
| SCHEMBL6643911 | 0.87 | EGFR (0.70) | EGFRERBB2GAK | |
| SCHEMBL5126158 | 0.85 | EGFR (0.53) | EGFRERBB2MAP2K1SRCMAP3K8 | |
| SCHEMBL5110365 | 0.85 | MAP2K1 (0.65) | EGFRERBB2MAP2K1MAP3K8 | |
| SCHEMBL4774191 | 0.85 | EGFR (0.55) | EGFRERBB2MAP2K1SRCMAP3K8 | |
| SCHEMBL4766988 | 0.85 | EGFR (0.69) | EGFRERBB2SRCGAKMAP3K8 | |
| SCHEMBL4774412 | 0.84 | EGFR (0.67) | EGFRERBB2MAP2K1SRCMAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1881981-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124944-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | EGFR 2871/4885ERBB2 1101/4885MAP2K1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.